Document:

EX-10.2

 EXHIBIT 10.2 
  

			
	

	  	29 Hartwell Avenue
	  	Lexington, MA 02421
	  	P (617) 945 7361

 March 19, 2021 
 Brendan
Smith 
 35 Park Street 
 Charlestown, MA 02129 

Re: Employment Agreement 
 Dear Brendan: 

On behalf of Translate Bio, Inc., a Delaware corporation (the “Company”), I am pleased to offer you the position of the
Company’s Chief Financial Officer & Corporate Strategy. Please note this offer is also contingent upon the successful completion of references and routine background checks and work authorization. 

 

	1.	 Position. Your position with the Company is Chief Financial Officer & Corporate Strategy and
you report to Ron Renaud, Chief Executive Officer. You agree to devote your full business time, best efforts, skill, knowledge, attention and energies to the advancement of the Company’s interests and the performance of your duties as an
employee of the Company and not to engage in any other business activities without prior approval of the Company. 

  

	2.	 Start Date. Your employment with the Company will begin on or before April 19, 2021. For
purposes of this Agreement, the actual first day of your employment with the Company shall be referred to as the “Start Date”. 

  

	3.	 Base Salary. The Company will pay you a salary at the bi-weekly
rate of $15,576.93 (which is equivalent to an annualized rate of $405,000.00 per year), payable in accordance with the Company’s standard payroll schedule and subject to applicable tax and other withholdings as required by law. Such base
salary may be subject to periodic review and adjustments at the Company’s sole discretion. 

  

	4.	 Discretionary Bonus. You will be eligible to receive an annual cash discretionary bonus of up to 45% of
your base salary (the “bonus”) in accordance with the terms of the applicable bonus plan. Your 2021 bonus will not be prorated based on your start date. The amount, if any, of the cash bonus payment, and the Company’s determination of
your performance, corporate objectives and business conditions at the Company are all within the sole discretion of the Company. Eligibility for and earning of the bonus, which is also a retention incentive that you remain employed by the Company,
requires the you be employed for the full period covered by the bonus as well as on the date the bonus is to be paid. Your eligibility for the bonus is also contingent on approval by the Board of Directors of the Company (the
“Board”). The Company expects to review your job performance on an annual basis and to discuss with you the criteria which the Company will use to assess your performance for bonus purposes. The Company also may make adjustments in
the targeted amount of your bonus in the Company’s sole discretion. 

  
 

 

	5.	 Benefits. You will be eligible to participate in the Company’s employee benefits and insurance
programs generally made available from time to time to its full-time employees, in accordance with, and provided you are eligible under, the plan documents governing those programs. You will also be eligible for up to 20 of days of paid vacation per
year which shall accrue on a prorated basis, in accordance with the Company’s vacation policy as in effect from time to time. The Company reserves the right to modify or terminate any or all of its benefit plans or policies at any time at its
discretion. 

  

	6.	 Incentive Equity Awards. Subject to approval by the Board, and as a material inducement to you entering
into employment with the Company, the Company will grant to you an option to purchase 201,800 shares of the Company’s common stock at a price per share equal to the fair market value per share of the Company’s common stock on the date of
grant (the “Proposed Grant”). The Proposed Grant will be subject to a vesting schedule as follows: one quarter of the shares subject to the option will vest on the first anniversary of the Start Date, and following that, 1/36th of the
remaining shares subject to the option will vest on a monthly basis, contingent on your continued employment with the Company. In connection with your ongoing employment, the Company may propose to the Board from time to time, that a stock option
grant be made to you of Company’ common stock pursuant to the Company’s 2018 Equity Incentive Plan (an “Additional Grant”). Any Proposed Grant or Additional Grant will be subject to the terms and conditions of an Option
Agreement to be entered into by you and the Company. Your ownership of the common stock will be subject to a vesting schedule and will be contingent on your continued employment or continuous service as a consultant or advisor with the Company.

 The Board may also, in its discretion, award you additional stock option grants or other equity awards subject to time
based and/or performance based vesting. The terms of the equity incentive plan and any associated award agreement (collectively the “Equity Documents”) shall apply to any equity grant. In the event of any conflict between the terms set
forth in this Agreement and the terms of the Equity Documents, the terms of the Equity Documents shall control. 
  

	7.	 Severance. Without otherwise limiting the “at-will”
nature of your employment, in the event your employment is terminated by the Company without Cause (as defined below) or you terminate for Good Reason, you shall be entitled to the base salary that has accrued and to which you are entitled as of the
effective date of such termination, and further, subject to the conditions set forth in the second paragraph of this Severance section, the Company shall, for a period of nine (9) months following your termination date: (i) continue to pay
you, in accordance with the Company’s regularly established payroll procedure, your base salary as Severance; and (ii) provided you are eligible for and timely elect to continue receiving group medical insurance pursuant to the
“COBRA” law, continue to pay the share of the premium for health coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage, unless the Company’s provision of such COBRA
payments will violate the non-discrimination requirements of applicable law, in which case this benefit will not apply. If, in the twelve months following a Change of Control, the Company terminates your
employment without Cause or you terminate for Good Reason, the Company, subject to the conditions set forth in the second paragraph of this Severance section, will: (a) extend the Severance benefits described in (i) and (ii) above for an
additional three (3) months, such that the total severance benefit period shall be 

  
 2 

	 	
twelve (12) months; (b) accelerate the vesting of all unvested stock options, restricted stock or other equity awards held by you as of the date your employment is terminated such that 100%
of such options, restricted stock or equity award shall become fully vested and, if applicable, exercisable effective as of such date (except as described in the next paragraph); and (c) pay to you a bonus amount equal to 1x your target annual
bonus for the year in which termination of employment occurs. 

 Notwithstanding the foregoing, you will not be entitled to
receive any severance benefits unless, within sixty (60) days following the date of termination, you (i) have executed a severance and release of claims agreement in a form prescribed by the Company or persons affiliated with the Company
(which will include, at a minimum, a release of all releasable claims and non-disparagement and cooperation obligations). Any severance payments shall commence on the first payroll period following the date
the release becomes effective (the “Payment Date”). Notwithstanding the foregoing, if the 60th day following the date of termination occurs in the calendar year following the calendar year of the termination, then the Payment Date
shall be no earlier than January 1st of such subsequent calendar year. Any stock options, restricted stock or equity award that would vest as a result of the prior paragraph will be treated as only provisionally vested and will only actually become
exercisable and/or alienable if and when you satisfy the release requirements, and any such provisionally vested portion will be deemed null and void retroactive to your date of termination if you either notify the Company that you will not execute
or will revoke the release or the period for providing the release expires without your complying with the release requirements. The Company may choose instead to provide to you any provisionally vested portions of these awards, subject to your
undertaking to repay the Company in the manner determined by the Company at such time if you fail to satisfy the release requirements thereafter. 

For purposes of this Agreement, “Cause” shall mean a finding by the Company in its sole discretion of any of the following:
(i) dishonesty, embezzlement, misappropriation of assets or property of the Company; (ii) gross negligence, willful misconduct, theft, fraud or breach of fiduciary duty to the Company; (iii) violation of federal or state securities
laws; (iv) your material breach of any written agreement between you and the Company; (v) the conviction of a felony, or any crime involving moral turpitude, including a plea of guilty or nolo contendre; or (vi) continued
nonperformance of your responsibilities, provided that, if the Company determines that such nonperformance can be cured, the Company has provided you with notice of such nonperformance and you have been provided with a reasonable opportunity to cure
not to exceed thirty (30) days. 
 For purposes of this Agreement, “Good Reason” shall mean that you have complied with
the “Good Reason Process” (hereinafter defined) following the occurrence of any of the following actions undertaken by the Company without your express prior written consent: (i) the material diminution in your responsibilities,
authority and function; (ii) a material reduction in your base salary, provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in your base salary that is pursuant to a salary reduction program
affecting substantially all of the senior level employees of the Company and that does not adversely affect you to a greater extent than other similarly situated employees; (iii) a material breach of your Agreement or any other written
agreement between you and the Company; or (v) a change in the geographic location at which you must regularly report to work and perform services to a location that is more than fifty (50) miles from Lexington, Massachusetts, except for
required travel on the Company’s business. “Good Reason Process” means that (i) you have reasonably determined in good faith that a “Good Reason” condition has occurred; (ii) you have notified the Company in
writing of the first 

  
 3 

 
occurrence of the Good Reason condition within sixty (60) days of the first occurrence of such condition; (iii) you have cooperated in good faith with the Company’s efforts, for a
period not less than thirty (30) days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your
employment within sixty (60) days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. 

For purposes of this Agreement, “Change in Control” shall mean any: (i) merger or consolidation in which the Company is a
constituent party or a subsidiary of the Company is a constituent party and the Company issues equity securities pursuant to such merger or consolidation, except any such merger or consolidation involving the Company or a subsidiary in which the
equity ownership of the Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for equity securities that represent, immediately following such merger or consolidation, at
least a majority, by both voting power and equity ownership, of (a) the surviving or resulting entity, or (b) if the surviving or resulting entity is a wholly owned subsidiary of another entity immediately following such merger or
consolidation, the parent entity of such surviving or resulting entity (provided that all capital stock issuable upon exercise of options outstanding immediately prior to such merger or consolidation or upon conversion of convertible securities
outstanding prior to such merger or consolidation shall be deemed to be outstanding immediately prior to such merger or consolidation and, if applicable, converted or exchanged in such merger or consolidation on the same terms as the actual
outstanding capital stock are converted or exchanged); (ii) sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company or any subsidiary of the Company of all or
substantially all the assets of the Company and its subsidiaries taken as a whole, or the sale or disposition (whether by merger or otherwise) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its
subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Company; (iii) any transfer of the Company’s
equity securities, or securities exchangeable for or convertible into the Company’s equity securities, if, immediately following the transfer, any one or more persons (other than the Company’s equity holders as of immediately prior to the
transfer) own a majority of the equity ownership or otherwise control a majority of the voting power of the Company; or (iv) any transfer of a subsidiary of the Company’s equity securities, or securities exchangeable for or convertible
into equity securities of such subsidiary, if, immediately following the transfer, any one or more persons ( other than the Company’s equity holders as of immediately prior to the transfer) own a majority of the equity ownership or otherwise
control a majority of the voting power of such subsidiary; provided that, where required for compliance with Section 409A, the event described in clauses (i)-(iv) is also a change in control event as set forth in Treas. Reg. Section 1.409A-3(i)(5). 
  

	8.	 Parachute Treatment. Notwithstanding any other provision of this Agreement to the contrary, if payments
and benefits provided for under this Agreement together with any payments or benefits under any other agreement or arrangement between the Company or any of its affiliates and you are considered “excess parachute payments” under
Section 280G of the Internal Revenue Code (the “Code”), then such excess parachute payments plus any other payments made by the Company and its affiliates that you are entitled to receive that are considered excess parachute
payments shall be limited to the greatest amount that may be paid to you under Section 280G of the Code without causing any loss of deduction to the Company under such Code Section, but only if, by reason of

  
 4 

	 	
such reduction, the “Net After Tax Benefit” (as defined below) to you shall exceed the net after tax benefit if such reduction was not made. “Net After Tax Benefit” for
purposes of this Agreement shall mean the sum of (i) the total amounts payable to you that would constitute an “excess parachute payment” within the meaning of Section 280G of the Code, less (ii) the amount of federal, state
and other income taxes payable with respect to the foregoing calculated at the maximum marginal tax rate for each year in which the foregoing shall be paid to you (based upon the rate in effect for such year as set forth in the Code at the time of
termination of your employment or the change in control), less (iii) the amount of excise taxes imposed with respect to the payments and benefits described above by Section 4999 of the Code. The determination of whether payments would be
considered excess parachute payments and the calculation of all the amounts referred to in this section shall be made reasonably and in good faith by the parties, provided, that if the parties cannot agree, then such determination (and supporting
calculations) shall be made by attorneys, accountants, or an executive compensation consulting firm each as selected by the Company at the expense of the Company (the “280G Service Providers”). Any determination by the 280G Service
Providers made in good faith shall be binding upon the Company and you. 

  

	9.	 Tax Acknowledgement. All forms of compensation referred to in this Agreement are subject to all
applicable federal, state and/or local withholding and/or payroll taxes, and the Company may withhold from any amounts payable to you in order to comply with such withholding obligations and you shall be responsible for all applicable taxes with
respect to such compensation. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its board of
directors related to tax liabilities arising from your compensation. You further acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of any of the compensation set forth in this
Agreement. 

  

	10.	 409A Compliance. This Agreement is intended to provide payments that are exempt from or compliant with
Section 409A, and should be interpreted consistent with that intent. The attached exhibit entitled “Payments Subject to Section 409A” is hereby appended to the Agreement as Attachment A and, if applicable, replaces any previous
such attachment concerning the same subject matter. 

  

	11.	 Confidential Information and Restricted Activities. By signing this Agreement, you represent that
you have carefully read and considered all the terms and conditions of this Agreement, including the restraints imposed on you pursuant to the Company’s Non-Competition,
Non-Solicit, Confidentiality and Invention Assignment Agreement (the “Restrictive Covenant Agreement”) attached as Attachment B, the terms of which are incorporated by reference herein. You
agree without reservation that these restraints are necessary for the reasonable and proper protection of the Company and its affiliates, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and
geographic area. You further agree that, if were you to breach any of the covenants contained in this Agreement or the Restrictive Covenant Agreement, in addition to the Company’s other legal and equitable remedies, the Company may suspend or
cease any Termination Benefits to which you might otherwise be entitled. Any such suspension or termination of the Termination Benefits by the Company in the event of a breach by you shall not affect your ongoing obligations to the Company.

  
 5 

	12.	 Interpretation, Amendment, Enforcement and Complete Agreement. This Agreement, the Employee Non-Competition, Non-Solicit, Confidentiality and Invention Assignment Agreement which you previously executed and which you reaffirm, and any plans and agreements applicable
to the incentive equity awards referred in Section 5 of this Agreement constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, amendments,
representations or understandings (whether written, oral or implied) between you and the Company. This Agreement shall be amended only by a writing signed by the Chief Executive Officer of the Company and you. The terms of this Agreement will be
governed by statutes and common law of The Commonwealth or Massachusetts without regard to the conflict of laws provisions. You and the Company hereby irrevocably submit to and acknowledge and recognize the exclusive personal jurisdiction of the
federal and state courts located in The Commonwealth of Massachusetts (which courts for purposes of this Agreement, are the only courts of competent jurisdiction) in connection with any dispute or any claim related to this Agreement or the subject
matter hereof. 

  

	13.	 At-Will Employment. Your employment with the Company will be on
an “at will” basis. In other words, you or the Company may terminate your employment for any reason and at any time, with or without cause. Although your job duties, title, compensation and benefits, as well as the Company’s benefit
plans and personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and the Company. 

[remainder of page intentionally left blank] 

  
 6 

 Please acknowledge, by signing below, that you have accepted this Agreement. 

 

			
	Very truly yours,
	
	TRANSLATE BIO, INC.
		
	By:	 	 /s/ Ronald C. Renaud, Jr.

		 	Ronald C. Renaud, Jr.
		 	Chief Executive Officer

 The foregoing correctly sets forth the terms of my employment by Translate Bio. I have read and accept the terms of this
Agreement. I am not relying on any representations pertaining to my employment other than those set forth above. 
 Accepted and Agreed as of March 22,
2021 
  

	
	 /s/ Brendan Smith

	Brendan Smith

  
 7 

 Attachment A 

Payments Subject to Section 409A 
 1.
Subject to this Attachment A, any severance payments that may be due under the letter agreement shall begin only upon the date of your “separation from service” (determined as set forth below) which occurs on or after the termination of
your employment. The following rules shall apply with respect to distribution of the severance payments, if any, to be provided to you under the letter agreement, as applicable: 

 

	 	a.	 It is intended that each installment of the severance payments under the letter agreement shall be treated as a
separate “payment” for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”). Neither the Company nor you shall have the right to accelerate or defer the delivery of any such
payments except to the extent specifically permitted or required by Section 409A. 

  

	 	b.	 If, as of the date of your “separation from service” from the Company, you are not a “specified
employee” (within the meaning of Section 409A), then each installment of the severance payments shall be made on the dates and terms set forth in the letter agreement. 

 

	 	c.	 If, as of the date of your “separation from service” from the Company, you are a “specified
employee” (within the meaning of Section 409A), then: 

  

	 	i.	 Each installment of the severance payments due under the letter agreement that is paid within the short-term
deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section l.409A-l(b)(4) to the maximum extent permissible under
Section 409A and shall be paid on the dates and terms set forth in the letter agreement; and 

  

	 	ii.	 Each installment of the severance payments due under the letter agreement that is not described in this
Attachment A, Section I (c)(i) and that would, absent this subsection, be paid within the six-month period following your “separation from service” from the Company shall not be paid until the date
that is six months and one day after such separation from service (or, if earlier, your death), with any such installments that are required to be delayed being accumulated during the six-month period and paid
in a lump sum on the date that is six months and one day following your separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding
provisions of this sentence shall not apply to any installment of payments if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the
application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation
Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of your second taxable year following the taxable year in which the separation from service occurs. 

 2. The determination of whether and when your separation from service from the Company has
occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1 (h). Solely for purposes of this Attachment A, Section 2,
“Company” shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414( c) of the Internal Revenue Code of 1986, as amended. 

3. The Company makes no representation or warranty and shall have no liability to you or to any other person if any of the provisions of the
letter agreement (including this Attachment) are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section.EX-10.3

 Exhibit 10.3 

CONSULTING AGREEMENT 
 THIS
CONSULTING AGREEMENT (this “Agreement”), made this 16th day of June, 2021 (the “Effective Date”), is entered into by and between Translate Bio, Inc., a Delaware corporation
(the “Company”), and Daniel S. Lynch, an individual residing at 18 Marlborough St, Boston, MA 02116 (the “Consultant”). 

INTRODUCTION 
 Consultant
is currently serving a three year term on the board of directors of the Company as a director and chairman of the board, which such term ending on June 16, 2021 (the “Term End Date”). The Company and the Consultant desire to
establish the terms and conditions under which the Consultant shall continue service to the Company from and after Term End Date. In consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties agree as follows: 
 1. Services. In the
role of senior advisor to the Company, the Consultant agrees to provide such advisory services to the Company as may be reasonably requested from time to time by the Company, including strategic advice and special projects. 

2. Term. This Agreement shall commence on the Term End Date and shall continue until the Consultant’s service is terminated in
accordance with the provisions of Section 4 (such period, the “Consultation Period”). 
 3.
Compensation. 
 3.1 Consulting Fee. During the Consultation Period, the Company shall pay to the Consultant consulting fees of
$8,333.33 per month ($100,000 on an annual basis), payable in arrears on the last day of each month. Payment for any partial month of service during the Consultation Period shall be prorated. 

3.2 Equity. During the Consultation Period, any equity awards previously granted by the Company to the Consultant shall continue to vest
and be exercisable, and the commencement of the Consultation Period immediately following the Term End Date shall be deemed not to create a cessation of service that would cause such awards either (y) to cease to vest or (z) to cease to be
exercisable after a set period of time following the Term End Date. 
 3.3 Expenses. The Company shall reimburse the Consultant for
all reasonable documented out of pocket expenses incurred or paid by the Consultant in connection with, or related to, the performance of his duties, responsibilities or services under this Agreement, including Consultant’s travel and lodging
expenses, upon presentation by the Consultant of documentation, expense statements, vouchers and/or such other supporting information as the Company may reasonably request. The Consultant shall submit to the Company itemized monthly statements of
such expenses incurred in the previous month. The Company shall pay to the Consultant amounts shown on each such statement within thirty (30) days after receipt thereof. The Company shall pay the reasonable and documented fees and expenses of
Moulton Law Group, PLLC, counsel for the Consultant, incurred in connection with the preparation and negotiation of this Agreement, not to exceed $2,500. 

 3.4 Benefits. The Consultant shall not be entitled to participate in any health or
dental benefit programs that the Company establishes and makes available to its employees, and shall not be entitled to participate in any other benefit programs that the Company establishes and makes available to its employees, if any. 

3.5 Taxes. The Consultant acknowledges and agrees that the Consultant is obligated to report as income all compensation received by the
Consultant pursuant to this Agreement, and the Consultant agrees to and acknowledge the obligation to pay all taxes including without limitation all federal and state income tax, social security taxes and unemployment, disability insurance and
workers’ compensation applicable to the Consultant. The Consultant shall indemnify and hold the Company harmless from any liability for, or assessment of, any such taxes imposed on the Company by relevant taxing authorities. 

4. Termination. This Agreement may be terminated by either the Company or the Consultant upon not less than ninety (90) days’
prior written notice to the other party; provided, however, that either party may terminate this Agreement immediately upon written notice to the other party in the event such other party has materially breached this Agreement. In the
event of any termination of this Agreement, the Consultant shall be entitled to payment of consulting fees hereunder and for expenses paid or incurred hereunder prior to the effective date of termination. 

5. Cooperation. The Company shall provide such access to its information and property as may be reasonably required in order to permit
the Consultant to perform his obligations hereunder. The Consultant shall cooperate with the Company’s personnel, shall not interfere with the conduct of the Company’s business and shall observe all rules, regulations and security
requirements of the Company concerning the safety of persons and property. 
 6. Proprietary Information, Inventions, and Non-Compete. 
 6.1 Proprietary Information. 

(a) The Consultant acknowledges that his relationship with the Company is one of high trust and confidence and that in the
course of his service to the Company he will have access to and contact with Proprietary Information. The Consultant shall not disclose any Proprietary Information to any person or entity other than employees, officers, directors, lawyers,
accountants and consultants of the Company or use the same for any purposes (other than in the performance of his duties as a consultant of the Company) without written approval by an officer of the Company, either during or after the Consultation
Period, unless and until such Proprietary Information has become public knowledge without fault by the Consultant. 

  
 - 2 - 

 (b) For purposes of this Agreement, Proprietary Information shall mean, by
way of illustration and not limitation, all information, whether or not in writing, whether or not patentable and whether or not copyrightable, of a private, secret or confidential nature, owned, possessed or used by the Company, concerning the
Company’s business, business relationships or financial affairs, including, without limitation, any Invention, formula, vendor information, customer information, apparatus, equipment, trade secret, process, research, report, technical or
research data, clinical data, know-how, computer program, software, software documentation, hardware design, technology, product, processes, methods, techniques, formulas, compounds, projects, developments,
marketing or business plan, forecast, unpublished financial statement, budget, license, price, cost, customer, supplier or personnel information or employee list that is communicated to, learned of, developed or otherwise acquired by the Consultant
in the course of performing his duties as a consultant of the Company. 
 (c) The Consultant’s obligations under this
Section 6.1 shall not apply to any information that (i) is or becomes known to the general public under circumstances involving no breach by the Consultant or others of the terms of this
Section 6.1, (ii) is generally disclosed to third parties by the Company without restriction on such third parties, or (iii) is approved for release by written authorization of an officer of the Company. 

(d) The Consultant agrees that all files, documents, letters, memoranda, reports, records, data sketches, drawings, models,
laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible material containing Proprietary Information, whether created by the Consultant or others, which shall come
into his custody or possession, shall be and are the exclusive property of the Company to be used by the Consultant only in the performance of his duties for the Company and shall not be copied or removed from the Company premises except in the
pursuit of the business of the Company. All such materials or copies thereof and all tangible property of the Company in the custody or possession of the Consultant shall be delivered to the Company, upon the earlier of (i) a request by the
Company or (ii) the termination of this Agreement. After such delivery, the Consultant shall not retain any such materials or copies thereof or any such tangible property. 

(e) The Consultant agrees that his obligation not to disclose or to use information and materials of the types set forth in
paragraphs (b) and (d) above, and his obligation to return materials and tangible property set forth in paragraph (d) above extends to such types of information, materials and tangible property of customers of the Company or suppliers to
the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Consultant. 
 (f)
The Consultant acknowledges that the Company from time to time may have agreements with other persons or with the United States Government, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during
the course of work under such agreements or regarding the confidential nature of such work. The Consultant agrees to be bound by all such obligations and restrictions that are known to him and to take all action necessary to discharge the
obligations of the Company under such agreements. 

  
 - 3 - 

 (g) Pursuant to the federal Defend Trade Secrets Act of 2016, the Consultant
shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or
indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under
seal. Further, nothing in this Agreement shall be interpreted or applied to prohibit the Consultant from making any good faith report to any governmental agency or other governmental entity concerning any acts or omissions that the Consultant
believes to constitute a possible violation of federal or state law or making other disclosures that are protected under the whistleblower provisions of applicable federal or state law or regulation. 

6.2 Inventions. 

(a) All inventions, creations, discoveries, computer programs, data, developments, technology, designs, innovations and
improvements (whether or not patentable and whether or not copyrightable) which are made, conceived, reduced to practice, created, written, designed or developed by the Consultant, solely or jointly with others or under his direction and whether
during normal business hours or otherwise, (i) during the Consultation Period if made, conceived, reduced to practice, created, written, designed or developed in the course of Consultant’s performance of duties pursuant to this Agreement
or (ii) during or after the Consultation Period if resulting or directly derived from Proprietary Information (collectively under clauses (i) and (ii), “Inventions”), shall be the sole property of the Company. The
Consultant hereby assigns and transfers and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company all Inventions and any and all related patents, copyrights, trademarks, trade names, and other
industrial and intellectual property rights and applications therefor, in the United States and elsewhere and appoints any officer of the Company as his duly authorized attorney to execute, file, prosecute and protect the same before any government
agency, court or authority. However, this paragraph shall not apply to Inventions which do not relate to the business or research and development conducted or planned to be conducted by the Company at the time such Invention is created, made,
conceived or reduced to practice and which are made and conceived by the Consultant not during normal working hours, not on the Company’s premises and not using the Company’s tools, devices, equipment or Proprietary Information. 

(b) Upon the request of the Company and at the Company’s expense, the Consultant shall execute such further assignments,
documents and other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other rights in the United
States and in any foreign country with respect to any Invention. The Consultant also hereby waives all claims to moral rights in any Inventions. 

  
 - 4 - 

 (c) The Consultant shall promptly disclose to the Company all Inventions and
shall maintain adequate and current written records (in the form of notes, sketches, drawings and as may be specified by the Company) to document the conception and/or first actual reduction to practice of any Invention. Such written records shall
be available to and remain the sole property of the Company at all times. 
 7. Other Agreements. The Consultant represents that his
performance of all of the terms of this Agreement do not and will not breach any agreement with any third party to which the Consultant is a party (including, without limitation, any nondisclosure or
non-competition agreement), and that the Consultant will not disclose to the Company or induce the Company to use any trade secrets, confidential or proprietary information or material belonging to any current
or previous employer or others. 
 8. Non-Exclusivity. The Consultant retains the right to be
employed or engaged by other companies and to contract with other companies or entities for his consulting services without restriction. 

9. Remedies. The Consultant acknowledges that any breach of the provisions of Section 6 shall result in
serious and irreparable injury to the Company for which the Company cannot be adequately compensated by monetary damages alone. The Consultant agrees, therefore, that, in addition to any other remedy it may have, the Company shall be entitled to
enforce the specific performance of this Agreement by the Consultant and to seek and obtain both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity of proving actual damages or posting a bond. 

10. Independent Contractor Status. The Consultant shall perform all services under this Agreement as an “independent
contractor” and not as an employee of the Company. 
 11. Notices. All notices required or permitted under this Agreement shall
be in writing and shall be deemed effective upon personal delivery or three days after deposit in the United States Post Office, by registered or certified mail (return receipt requested), postage prepaid, addressed to the other party at the address
shown above, or at such other address or addresses as either party shall designate to the other in accordance with this Section 11. 

12. Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine
or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 
 13. Entire Agreement. This
Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement. 

14. Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Consultant.

 15. Non-Assignability of Contract by the Consultant. This Agreement is personal to the
Consultant and the Consultant shall not have the right to assign any of his rights or delegate any of his duties without the express written consent of the Company. Any
non-consented-to assignment or delegation, whether express or implied or by operation of law, shall be void and shall constitute a breach and a default by the
Consultant. 

  
 - 5 - 

 16. Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the Commonwealth of Massachusetts without giving effect to any choice or conflict of law provision or rule that would cause the application of laws of any other jurisdiction. 

17. Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective
successors and assigns, including any entity with which, or into which, the Company may be merged or consolidated or which may succeed to its assets or business; provided, however, that the obligations of the Consultant are personal
and shall not be assigned by him. 
 18. Interpretation. If any restriction set forth in Section 6 is found
by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of
time, range of activities or geographic area as to which it may be enforceable. 
 19. Survival. Section 4
and Sections 6 through 21 shall survive the termination of this Agreement. 
 20. Section 409A. 

20.1 To the extent that any payment or benefit described in this Agreement constitutes
“non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Consultant’s termination of service, then such
payments or benefits shall be payable only upon the Consultant’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation Section 1.409A-1(h). 
 20.2 The parties intend that this Agreement will be
administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments
hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The
parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and
benefits provided hereunder without additional cost to either party. 
 20.3 The Company makes no representation or warranty and shall have
no liability to the Consultant or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such
Section. 

  
 - 6 - 

 21. Miscellaneous. 

21.1 No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. No
waiver of any term or condition of this Agreement shall be valid or binding on either Party unless the same shall have been mutually assented to in writing by both Parties. The failure of either Party to enforce at any time any of the provisions of
this Agreement, or the failure to require at any time performance by the other Party of any of the provisions of this Agreement, shall in no way be construed to be a present or future waiver of such provisions, nor in any way affect the right of
either Party to enforce each and every such provision thereafter. The express waiver by either Party of any provision, condition or requirement of this Agreement shall not constitute a waiver of any future obligation to comply with such provision,
condition or requirement. 
 21.2 The captions of the sections of this Agreement are for convenience of reference only and in no way define,
limit or affect the scope or substance of any section of this Agreement. 
 21.3 In the event that any provision of this Agreement shall be
invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

[Remainder of Page Intentionally Left Blank] 

  
 - 7 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Consulting Agreement as of the day
and year set forth above. 
  

			
	TRANSLATE BIO, INC.
		
	By:	 	 /s/ Paul Burgess

	Name: Paul Burgess
	Title: Chief Operating Officer and Chief Legal Officer
	
	CONSULTANT
	
	 /s/ Daniel S. Lynch

	Daniel S. Lynch

 [Signature Page to Consulting Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}]]